Clinical Trials
8 trialsNCT01578499 2021-01-05
ALCANZA
Takeda
Phase 3 Completed
NCT01134341 2019-12-18
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Acrotech Biopharma Inc.
Phase 1 Completed
NCT01007448 2019-11-12
Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)
Bausch Health Americas, Inc.
Phase 4 Completed
NCT00255801 2018-08-16
Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00178841 2016-02-17
Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL
Vanderbilt University
Phase 2 Completed
NCT00660231 2014-12-03
GemBex
University College, London
Phase 2 Completed
NCT00030849 2013-04-04
Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00306969 2006-03-27
Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma
Boston University
Phase 1/2 Completed